Lipid profiles for etravirine versus efavirenz in treatment-naive patients in the randomized, double-blind SENSE trial.

Fätkenheuer G, Duvivier C, Rieger A, Durant J, Rey D, Schmidt W, Hill A, van Delft Y, Marks S J Antimicrob Chemother. 2012 Mar,67(3):685-90. doi: 10.1093/jac/dkr533. Epub 2011 Dec 29.

An international expanded-access programme of everolimus: addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy.

GrГјnwald V, Karakiewicz PI, Bavbek SE, Miller K, Machiels JP, Lee SH, Larkin J, Bono P, Rha SY, Castellano D, Blank CU, Knox JJ, Hawkins R, Anak O, Rosamilia M, Booth J, Pirotta N, Bodrogi I Eur J Cancer. 2012 Feb,48(3):324-32. doi: 10.1016/j.ejca.2011.06.054. Epub 2011 Jul 29.

A 55-year-old woman with locally advanced rectal cancer and a resectable synchronous hepatic metastasis: a case report.

Hohla, F, Mayer, P, Hutter, J, MeiГџnitzer, T, Greil, R, memo – Magazine of European Medical Oncology. 2012, 5 (4): 273-276.

The role of biomarkers in the choice of therapy in triple negative breast cancer

Mlineritsch B Ressler S Greil R memo – Magazine of European Medical Oncology. 2012, 5: 101-104.

Lenalidomide/Rituximab Maintenance After Induction With Fludarabine/Rituximab In Combination With Escalating Doses Of Lenalidomide In Previously Untreated Chronic Lymphocytic Leukemia (CLL): The Revlirit CLL5 AGMT Phase I/II Study, Final Results

Vornamen sind ausgeschrieben-Г¤ndern? Alexander Egle, Michael Steurer, Franz Josef Gassner, Roland Geisberger, Thomas Melchardt, Lisa Pleyer, Lukas Weiss, Michael A. Fridrik, Josef Thaler, Alois Lang, Richard Greil, Blood (ASH Annual Meeting Abstracts). 2013. #4164:

Dose-intensification in early unfavorable Hodgkin’s lymphoma: final analysis of the German Hodgkin Study Group HD14 trial.

von Tresckow B, PlГјtschow A, Fuchs M, Klimm B, Markova J, Lohri A, Kral Z, Greil R, Topp MS, Meissner J, Zijlstra JM, Soekler M, Stein H, Eich HT, Mueller RP, Diehl V, Borchmann P, Engert A. J Clin Oncol. 2012 Mar 20,30(9):907-13. doi: 10.1200/JCO.2011.38.5807. Epub 2012 Jan 23.

[Primary immune thrombocytopenia in adults: diagnostics and treatment consensus statement of the Austrian Society of Hematology and Oncology (ÖGHO)].

Pabinger I, Gastl G, Steurer M, Sormann S, Fillitz M, Friedl J, Geissler D, Geissler K, Greil R, Knöbl P, Kozek-Langenecker S, Krippl P, Kyrle P, Lang A, Linkesch W, Ludwig H, Müller M, Panzer S, Pittermann E, Thaler J, Weltermann A. Wien Klin Wochenschr. 2012 Feb,124(3-4):111-23. doi: 10.1007/s00508-012-0123-3. Epub 2012 Mar 3.

Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin’s lymphoma (HD15 trial): a randomised, open-label phase 3 non-inferiority trial.

Engert A, Haverkamp H, Kobe C, Markova J, Renner C, Ho A, Zijlstra J, Král Z, Fuchs M, Hallek M, Kanz L, Döhner H, Dörken B, Engel N, Topp M, Klutmann S, Amthauer H, Bockisch A, Kluge R, Kratochwil C, Schober O, Greil R, et al. Lancet. 2012 May 12,379(9828):1791-9. doi: 10.1016/S0140-6736(11)61940-5. Epub 2012 Apr 4.

LICC: L-BLP25 in patients with colorectal carcinoma after curative resection of hepatic metastases: a randomized, placebo-controlled multicenter multinational double-blinded phase II trial.

Schimanski CC, Möhler M, Schön M, van Cutsem E, Greil R, Bechstein WO, Hegewisch-Becker S, von Wichert G, Vöhringer M, Heike M, Heinemann V, Peeters M, Kanzler S, Kasper S, Overkamp F, Schröder J, Seehofer D, Kullmann F, Linz B, Schmidtmann I, Smith-Machnow V, Gockel I, et al. BMC Cancer. 2012 Apr 11,12:144. doi: 10.1186/1471-2407-12-144.

Effect of KRAS codon13 mutations in patients with advanced colorectal cancer (advanced CRC) under oxaliplatin containing chemotherapy. Results from a translational study of the AIO colorectal study group.

Reinacher-Schick A, Schulmann K, Modest DP, Bruns N, Graeven U, Jaworska M, Greil R, Porschen R, Arnold D, Schmiegel W, Tannapfel A. BMC Cancer. 2012 Aug 9,12:349. doi: 10.1186/1471-2407-12-349.